The United Kingdom and the United States have concluded a key bilateral deal that will preserve no duties on British drug exports going into the American market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these crucial products will remain at zero for a timeframe of the next three years.
This agreement comes after earlier warnings to hike tariffs on branded drug products, with increases discussed up to double the cost.
"This agreement with the Britain reinforces the international landscape for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," a release declared.
Economic Significance
Medicines are one of the the United Kingdom's largest exports to the United States, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to September, the UK exported pharmaceutical products valued at billions to the US. This value accounted for 17.4% of total UK exports in that span.
"This deal secures employment, boosts investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Specific NHS Changes
The pact involves several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments topped 20%.
Recent Tensions
This agreement comes amid a ongoing tension between the sector and the UK government over medicine costs and NHS adoption.
This friction were intensified by claims that American customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its total funding over the past decade.
